RAPT (rapt.com) Market Value to Book Value Ratio
RAPT Therapeutics, Inc. (RAPT) management is currently revising its strategy following research pauses, leaving market confidence moderate. The business relies on developing oncology and allergy treatments, which ensures stable demand. This daily price action reflects a value of 6.50. Risks are minimized by diversifying development across two distinct medical fields, protecting the company from potential clinical trial failures.
%3A%20Market%20Capitalization%20to%20Net%20Assets&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_RAPT_-_RAPT-Therapeutics-Inc._-_Market-Capitalization-to-Net-Assets "RAPT rapt.com Market Capitalization to Book Value Ratio (07/04/2022 - 03/14/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for RAPT Therapeutics Inc. (RAPT)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Initial company analysis:RAPT Therapeutics - RAPT
To identify fundamentally resilient assets, investors analyze asset quality by comparing market value with net assets. This price-to-book ratio reflects the capital premium, which for RAPT Therapeutics, Inc. (RAPT) depends directly on the success of clinical trials and the removal of regulatory restrictions, thereby determining the fair valuation of future R&D achievements.
Main competitors
ARGX - Market Cap to Net Assets Ratio|BNTX (biontech.de) - Market Cap to Book Value Multiple|Market Value to Book Value Ratio abivax.com ABVX|Market Capitalization to Net Assets ADMA Biologics Inc|Protagonist Therapeutics Inc (PTGX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Immunovant Therapeutics (IMVT)|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|grifols.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Adaptive Biotechnologies Corporation (ADPT)|CLDX: Market Value to Book Value|AUPH (Aurinia Pharma) - Market Value to Book Value Ratio|BioCryst Corp (BCRX) - Market Cap to Net Assets Ratio|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com (DNTH)|Pharvaris (PHVS) - Market Cap to Net Assets Ratio|Market Value to Book Value AbCellera Biologics (ABCL)|Market Capitalization to Book Value Ratio TRML|Precigen Corp - Market Capitalization to Book Value|PHAR: Market Value to Book Value Ratio|NKTR: Market Cap to Net Assets Ratio|UPB (Upstream Bio) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Zenas Bio|IMNM (Immunome Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio GOSS|Market Value to Book Value Ratio KalVista Pharmaceuticals KALV|Capitalization to Book Value Ratio septerna.com (SEPN)|PVLA: Market Capitalization to Book Value Ratio|Savara Inc - Market-to-Book Ratio|Market Value to Book Value Ratio Rigel Pharmaceuticals Inc (RIGL)|ANAB - Market Value to Book Value|ATXS: Market Capitalization to Book Value Ratio|ENGN (engene.com) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Aerovate Therapeutics, Inc. JBIO|Market Capitalization to Net Assets Aclaris Therapeutics Inc. (ACRS)|Market Cap to Net Assets Ratio Kyverna|Market Cap to Book Value Multiple Tiziana Life Sciences, Ltd. TLSA|Market Cap to Net Assets Ratio Cabaletta Bio, Inc.|VTYX - Market Value to Book Value|Market Cap to Net Assets Ratio Theratechnologies THTX|AVTX - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio Eledon ELDN|Agenus, Inc (AGEN) - Market Value to Book Value|Market Capitalization to Book Value Ratio CLYM (Climb Bio Inc)|Market-to-Book Ratio ZURA|aTyr Pharma (ATYR) - Market Value to Book Value Ratio|Market Value to Book Value adagene.com (ADAG)|Market Capitalization to Book Value Ratio IMA (Ikena Oncology)|Shattuck Labs Inc - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Equillium Bio|CNTB - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio IMUX|Market-to-Book Ratio Atara Bio|IFRX (InflaRx NV) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio X4 Pharmaceuticals, Inc (XFOR)|Market Cap to Net Assets Ratio Adicet Bio|Market Cap to Book Value Multiple celularity.com (CELU)|Market Capitalization to Book Value Ratio INMB|Market Capitalization to Book Value Barinthus Biotherapeutics PLC BRNS|KZR: Market Capitalization to Book Value Ratio|SABS: Market Cap to Net Assets Ratio|Akari Therapeutics - Market Value to Book Value Ratio|Market Capitalization to Book Value Enlivex Therapeutics Ltd.|QTTB - Market Cap to Net Assets Ratio|Market Value to Book Value GeoVax Labs|EDSA (Edesa) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value IBIO (iBio Corporation)|CARM - Market Value to Book Value Ratio|Capitalization to Book Value Ratio xtlbio.com XTLB|BOLT: Market Capitalization to Book Value Ratio|HCW Biologics Inc. (HCWB) - Market Cap to Net Assets Ratio|aptevotherapeutics.com - Market Cap to Net Assets Ratio|AIM (aimimmuno.com) - Market Capitalization to Book Value|ADTX - Market Value to Book Value Ratio|Market Value to Book Value gribio.com|Market Capitalization to Book Value Ratio XRTX|Market Capitalization to Book Value Ratio HIND (Vyome Holdings Inc.)|Revelation Bio (REVB) - Market Value to Book Value Ratio|INDP - Market Capitalization to Net Assets|Market Cap to Net Assets Ratio Scinai Immunotherapeutics SCNI|CALI: Market Cap to Book Value Multiple|Market Value to Book Value Ratio affimed.com (AFMD)|Allakos (ALLK) - Market Capitalization to Net Assets|HOOK - Market Capitalization to Book Value Ratio|Market Value to Book Value IGM Bio|Market Capitalization to Book Value Ratio ITOS|Market Capitalization to Book Value Ratio OCEA (oceanbiomedical.com)|Market Value to Book Value Ratio TC BioPharm|Third Harmonic Bio Inc. - Market Value to Book Value